胃间质瘤患者辅助治疗前CDK4和TP53突变水平与预后的相关性

张帅; 申昌军

doi:10.3969/j.issn.1671-038X.2020.09.11

胃间质瘤患者辅助治疗前CDK4和TP53突变水平与预后的相关性

张帅,
申昌军^,

- 延安市人民医院普外科, 陕西延安 716000

详细信息

通讯作者: 申昌军,E-mail:zhang76shuau@163.com

中图分类号: R735.2

收稿日期: 2019-09-04

Correlation between CDK4 and TP53 gene mutations and prognosis in patients with gastric stromal tumors before adjuvant therapy

ZHANG Shuai,
SHEN Chang-jun^,

- Department of General Surgery, Yan'an People's Hospital, Yan'an 716000, China

More Information

Corresponding author: SHEN Chang-jun, E-mail: zhang76shuau@163.com

Received Date: 04 September 2019

摘要

摘要: [目的]比较高复发转移风险与非高复发转移风险胃间质瘤(GST)患者TP53和CDK4基因的表达水平差异,TP53和CDK4基因的表达水平对高复发转移风险GST患者术后伊马替尼辅助治疗的预后影响。[方法]前瞻性纳入收治行根治切除术的143例原发性GST患者,根据《中国胃肠间质瘤诊断治疗专家共识》将原发性GST患者分为高风险组(62例)和非高风险组(81例)。术后取瘤组织做免疫组化检测,比较2组间p53(TP53基因编码的蛋白)和CDK4表达情况。高风险组给予术后伊马替尼辅助治疗,再根据免疫组化结果,将62例高风险组患者分为p53高表达组、p53低表达组和CDK4高表达组、CDK4低表达组进行亚组分析。分别比较高表达组和低表达组间5年无事件生存率。[结果]高风险组和低风险组的年龄和性别比例差异无统计学意义。而高风险组的原发肿瘤大小较非高风险组大,分别为(11.53±2.81)cm、(8.25±1.52)cm(P<0.001),且肿瘤的核分裂数较非高风险组多,分别为12.24±2.32、7.52±2.21(P<0.001)。免疫组化结果提示,高风险组p53蛋白表达水平较非高风险组高,而CDK4蛋白表达水平较非高风险组低。在高风险组中,p53高表达组的5年无事件生存率较低表达组低,分别为45.6%、78.4%(P=0.044);然而,CDK4高表达组的5年无事件生存率较低表达组高,分别为74.2%、48.4%(P=0.029)。[结论]高复发、高转移风险的GST患者TP53基因表达水平较高;CDK4表达水平较低。更高的TP53基因表达和更低的CDK4表达水平提示着高复发、转移风险的GST术后伊马替尼辅助治疗有更好的预后。
- 胃间质瘤 /
- 术后辅助治疗 /
- 伊马替尼 /
- TP53基因 /
- CDK4基因 /
- 预后
Abstract: [Objective]Comparing the expression levels of TP53 and CDK4 genes in patients with high risk of recurrence and metastasis and those with non-high risk of recurrence and metastasis, and the effect of TP53 and CDK4 gene expression levels on the prognosis of postoperative imatinib adjuvant therapy in patients with high risk of recurrence and metastasis.[Methods]A prospective enrollment of 143 patients with primary GST who underwent radical resection in our hospital was divided into high-risk groups(62 patients)and non-surgical patients according to the consensus of Chinese gastrointestinal stromal tumor diagnosis and treatment experts.High risk group(81 cases).The tumor tissues were taken for immunohistochemistry,and the expression of p53(protein encoded by TP53 gene)and CDK4 were compared between the two groups.High-risk group was given adjuvant treatment with imatinib.According to the results of immunohistochemistry,62 high-risk patients were divided into p53 high expression group,p53 low expression group and CDK4 high expression group,and CDK4 low expression group.Group analysis.Five-year event-free survival rates were compared between the high-expression and low-expression groups,respectively. [Results]There were no significant differences in age(58.22 ± 5.21,56.74 ± 6.21)and sex ratio(37/25,51/30)between the high-risk and low-risk groups included in the study(P>0.05).The size of the primary tumor in the high-risk group was larger than that in the non-high-risk group,which was(11.53±2.81)cm,(8.25±1.52)cm(P<0.001),and the number of mitotic divisions in the tumor was higher than that in the non-high-risk group,which was 12.24±2.32,7.52±2.21,P<0.001.The results of immunohistochemistry indicated that the expression level of p53 protein in high-risk group was higher than that in non-high-risk group,while the expression level of CDK4 protein was lower than that in non-high-risk group.In the high-risk group,the five-year event-free survival rate was lower in the low-expression group of the p53-high expression group,45.6%,78.4%,P=0.044.However,CDK4 was highly expressed.The group's five-year event-free survival rate was lower in the expression group,which was 74.2%,48.4%,P=0.029. [Conclusion]Gastric stromal tumors with high recurrence and metastasis risk have higher TP53 gene expression level and lower CDK4 expression level.Higher TP53 gene expression and lower CDK4 expression levels suggest a better prognosis for the prognosis of patients with high recurrence and metastatic gastric stromal tumors after imatinib adjuvant therapy.
- gastric stromal tumor /
- adjuvant therapy /
- imatinib /
- TP53 gene /
- CDK4 gene /
- prognosis

HTML全文

参考文献(22)

[1]	Luo XF,Zhou L H.Prognostic significance of neutrophil to lymphocyte ratio in patients with gastrointestinal stromal tumors:A meta-analysis[J].Clin Chim Acta,2017,477(1):7-12.
[2]	Gomes A,Bardales RF,Reis R,et al.Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS[J].Am J Clin Pathol,2015,127(1):89-96.
[3]	Ahmad F,Lad P,Bhatia S,et al.Molecular spectrum of c-KIT and PDGFRA gene mutations in gastro intestinal stromal tumor:determination of frequency,distribution pattern and identification of novel mutations in Indian patients[J].Med Oncol,2015,32(1):1-11.
[4]	Wang Y,Fletcher JA.Cell cycle and dystrophin dysregulation in GIST[J].Cell Cycle,2015,14(17):2713-2714.
[5]	Neves LR,Oshima CT,Artigianineto R,et al.Ki67 and p53 in gastrointestinal stromal tumors-GIST[J].Arq Gastroenterol,2009,46(2):116-120.
[6]	Al-Bozom I A.p53 expression in gastrointestinal stromal tumors[J].Pathol Int,2010,51(7):519-523.
[7]	周东,毕瑞雪,杨勇 ,等.FAK在胃肠道间质瘤组织中的表达及其与诊断治疗关系的研究[J].医学信息,2016,29(26):226-228.
[8]	Kubota T.Gastrointestinal stromal tumor(GIST)and imatinib[J].Int J Clin Oncol,2006,11(3):184-189.
[9]	Van Glabbeke MM,Owzar K,Rankin C,et al.Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors(GIST):A meta-analyis based on 1,640 patients(pts)[J].J Clin Oncol,2010,28(7):1247-1253.
[10]	Joensuu H,Rutkowski P,Nishida T,et al.KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence[J].J Clin Oncol,2015,33(6):634-642.
[11]	Dematteo RP,Gold JS,Saran L,et al.Tumor mitotic rate,size,and location independently predict recurrence after resection of primary gastrointestinal stromal tumor(GIST)[J].Cancer,2010,112(3):608-615.
[12]	CSCO胃肠间质瘤专家委员会.中国胃肠间质瘤诊断治疗专家共识(2011年版)[J].临床肿瘤学杂志,2011,16(9):836-844.
[13]	王志生,李晓辉,任飞,等.免疫组化染色的操作技巧和注意事项[J].中国实用医药,2014,9(15):240-240.
[14]	Clark BZ,Dabbs DJ,Cooper KL,et al.Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score:a quality assurance study of 1074 cases[J].Appl Immunohistochem Mol Morphol,2013,21(4):287-291.
[15]	Zhu X,Yang S,Lin W,et al.Roles of Cell Cyle Regulators Cyclin D1,CDK4,and p53 in Knee Osteoarthritis[J].Genet Test Mol Biomarkers,2016,20(9):529-534.
[16]	Liao P,Zeng SX,Zhou X,et al.Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding[J].Mol Cell,2017,68(6):1134-1146.
[17]	Leroy B,Anderson M,Soussi T.TP53 Mutations in Human Cancer:Database Reassessment and Prospects for the Next Decade[J].Hum Mutat,2014,35(6):672-688.
[18]	Ohnstad HO,Castro R,Sun J,et al.Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma[J].Cancer,2013,119(5):1013-1022.
[19]	Muller PAJ,Trinidad AG,Timpson P,et al.Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion[J].Oncogene,2013,32(10):1252-1265.
[20]	Somasundaram K.Tumor suppressor p53:regulation and function[J].Front Biosci,2000,5(5):424-437.
[21]	Muller PAJ,Vousden KH.p53 mutations in cancer[J].Nat Cell Biol,2013,15(1):2-8.
[22]	Ihle MA,Huss S,Jeske W,et al.Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment[J].Plos One,2018,13(2):e0193048.